Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “TPTX.”
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Donald K. Lang, Daniel Reichert and Dana Lueck-Mammen. The tax team included counsel Ethan R. Goldman and associate M. Jared Sanders. The intellectual property and technology transactions team included counsel Daniel F. Forester and associate Jennifer Leather. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.